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ABSTRACT: The peroxisome proliferator-activated receptors
(PPAR) are ligand-activated transcription factors that belong to
the nuclear hormone receptor family. Three isotypes (PPARα,
PPARβ or δ, and PPARγ) with distinct tissue distributions and
cellular functions have been found in vertebrates. All three PPAR
isotypes are expressed in rodent and human skin. They were ini-
tially investigated for a possible function in the establishment of
the permeability barrier in skin because of their known function
in lipid metabolism in other cell types. In vitro studies using spe-
cific PPAR agonists and in vivo gene disruption approaches in
mice indeed suggest an important contribution of PPARα in the
formation of the epidermal barrier and in sebocyte differentiation.
The PPARγ isotype plays a role in stimulating sebocyte develop-
ment and lipogenesis, but does not appear to contribute to epi-
dermal tissue differentiation. The third isotype, PPARβ, regulates
the late stages of sebaceous cell differentiation, and is the most
effective isotype in stimulating lipid production in these cells,
both in rodents and in humans. In addition, PPARβ activation
has pro-differentiating effects in kera-tinocytes under normal
and inflammatory conditions. Finally, preliminary studies also
point to a potential role of PPAR in hair follicle growth and in
melanocyte differentiation. By their diverse biological effects
on cell proliferation and differentiation in the skin, PPAR ago-
nists or antagonists may offer interesting oppotunities for the
treatment of various skin disorders characterized by inflamma-
tion, cell hyperproliferation, and aberrant differentiation.
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Peroxisome proliferator-activated receptors (PPAR) belong,
together with the receptors for thyroid hormones, retinoids,
steroid hormones, and vitamin D, to the nuclear hormone re-
ceptor family. They require heterodimerization with the
retinoid X receptors (RXR, NR2B) for binding to DNA as lig-
and-activated transcription factors that regulate the expres-
sion of target genes containing peroxisome proliferator re-
sponse elements (PPRE) in their promoters. The PPAR sub-
family consists of three isotypes, which are named PPARα
(NR1C1), PPARβ or δ (NR1C2), and PPARγ (NR1C3). Each
isoform is characterized by a distinct tissue distribution and
specific functions (1). PPARα has a main function in FA ca-
tabolism in the liver, and regulates amino acid metabolism,
urea synthesis, and inflammatory responses (1,2). PPARγ
plays a pivotal role in adipocyte differentiation and then in
maintenance of the differentiated state, as well as in lipid stor-
age. Furthermore, like PPARα, it has been implicated in the
downregulation of multiple inflammatory processes (1,2).
PPARβ is the most ubiquitously expressed isotype, but little
is known about its functions, mainly because of the lack, until
recently, of selective PPARβ agonists. Nevertheless, recent
studies have suggested a role for PPARβ in embryonic devel-
opment, colon tumorigenesis, skin wound healing, fat catabo-
lism, and oligodendrocyte differentiation (3,4).
Specific roles for PPAR in vertebrate development have
emerged from both in vitro and in vivo models, in particular
during the differentiation of adipose tissue, brain, and pla-
centa in mice (5). The importance of PPAR in lipid metabo-
lism in various cell types has led to the investigation of PPAR
expression and function during the differentiation of skin,
which is a tissue with high rates of FA and cholesterol metab-
olism largely devoted to the formation of the epidermal per-
meability barrier. During skin development, several nuclear
hormone receptors, including the estrogen, thyroid, androgen,
and retinoid receptors, and their respective ligands have been
implicated in the ontogeny of the epidermal barrier, hair folli-
cle growth, and skin homeostasis (6,7).
In this review, we will summarize the PPAR functions re-
cently identified in skin homeostasis, including epidermal
barrier formation, hair follicle growth, sebocyte differentia-
tion, and melanogenesis.
MAIN FUNCTIONS OF PPARα AND PPARβ IN THE
HEALTHY AND INJURED EPIDERMIS
The epidermis is renewed continuously and its integrity is de-
pendent on a tightly regulated balance between cell prolifera-
tion, differentiation, and apoptosis. During its maturation,
which happens mainly in the latest stages of fetal develop-
ment, the epidermis evolves from a single layer of epithelial
cells (periderm) to a fully stratified and differentiated epithe-
lium (Fig. 1). This process involves the sequential expression
of structural proteins (keratins, involucrin, loricrin, and filag-
grin) and synthesis of specific lipids (sphingolipids, FFA, and
cholesterol). The outermost layer of the epidermis, the stra-
tum corneum, is the end product of keratinocyte differentia-
tion and consists of a layer of cross-linked proteins and lipids,
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which functions as a barrier to transepidermal water loss and
as a defense against physical damage, microbes, and xenobi-
otics.
During mouse and rat embryonic development, all three
PPAR isotypes, and predominantly PPARβ, have been de-
tected in the interfollicular epidermis from embryonic day
13.5 (E13.5) onward (3,8). Interestingly, PPAR expression is
associated with all major events of the fetal maturation of the
epidermal barrier. After birth, PPAR gradually disappear from
the interfollicular epidermis to become undetectable in the
adult animals (Fig. 1) (3,9). In contrast, the three PPAR iso-
types are highly expressed in the basal and suprabasal layers
of human adult interfollicular epidermis (Fig. 1), with PPARβ
being again the predominant subtype (10,11). Consistent with
the expression pattern of PPAR in the developing rodent skin,
several reports have concentrated on the involvement of
PPAR in processes such as cell proliferation, differentiation,
and permeability barrier development (see Table 1). A vari-
ety of PPARα activators, including clofibrate, were shown to
accelerate the morphologic and functional maturation of the
epidermal permeability barrier in fetal rat skin both in vitro and
in vivo (12–14). This is evidenced by decreased transepidermal
water loss, increased epidermal stratification, and increased ex-
pression of the two specific late keratinocyte differentiation
markers, loricrin and filaggrin. PPARα ligands also inhibit epi-
dermal proliferation and induce keratinocyte differentiation in
adult mouse epidermis in vivo (15,16). Furthermore, these ac-
tivators restore epidermal homeostasis in murine models of
hyperproliferative epidermis (17). In contrast, the two PPARγ
ligands, troglitazone and prostaglandin J2, did not affect the
development of barrier function or epidermal morphology in
fetal rat skin (12), and no specific function in skin maturation
has been attributed so far to this isotype (Table 1). In favor of
a potential role of PPARβ in epidermal differentiation in ro-
dents, the pan PPAR(α/β) activator linoleic acid (18) was
shown to accelerate epidermal barrier development in fetal
rat skin explants (12). In addition, an important role of
PPARβ in mediating keratinocyte differentiation induced by
inflammation was demonstrated in mouse primary ker-
atinocytes (19). Importantly, the PPARβ-selective agonist
GW1514 stimulated mouse epidermal differentiation without
affecting cell proliferation in vivo, by inducing the expression
of the late differentiation markers filaggrin and loricrin (20).
Also, topical treatment of mice with GW1514 accelerates the
restoration of permeability barrier functions after disruption
by tape stripping, solvent, or detergent treatment (20), in sup-
port of the importance of the pro-differentiating effect of
PPARβ activation.
Novel information on the role of PPAR in epidermis homeo-
stasis also came from PPAR mutant mouse models. Although
normal skin architecture was initially reported in PPARα-
knockout mice (5,21), these animals show delayed fetal skin de-
velopment between E18.5 and birth, with defects in the forma-
tion of the stratum corneum (22). Morphologic analysis of adult
PPARα-null epidermis revealed a thinned stratum granulosum,
with focal parakeratosis, indicative of impaired keratinocyte dif-
ferentiation (15). Thus, consistent with its expression pattern,
PPARα might be important for the maturation of the epidermis
during late embryogenesis, but dispensable for normal renewal
of the epidermis in the adult animals. Interestingly, PPARα also
regulates the early inflammation phase during skin wound heal-
ing, as the recruitment of immune cells to the wound site is im-
paired in PPARα-null mice (3). PPARγ heterozygous mice, or
PPARγ-null mice born after placental rescue, show no defect in
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FIG. 1. Schematic representation of interfollicular epidermis development. During late fetal
development (between embryonic day E13.5 and the end of gestation) in mouse skin, the epi-
dermis changes from a single basal undifferentiated layer (basal layer) covered by a transient
superficial layer of cells (periderm), to a fully stratified and differentiated epithelium, with se-
quential formation of suprabasal layers (spinous and granular layers). The end product of dif-
ferentiation resides on the surface of the epidermis (stratum corneum) and provides the main
permeability barrier of the skin. Expression patterns of PPARα (α), PPARβ (β), and PPARγ (γ)
determined or not (nd) during mouse (3) and rat (8,9) epidermal development, and in human
adult interfollicular epidermis (10,11), are summarized in the bottom panel.
epidermal maturation (3,23). In addition, PPARγ-null cells are
able to participate in the formation of the epidermal tissue in
PPARγ-null and wild-type chimeric mice, suggesting very little
or no contribution of PPARγ in this process (24). Analysis of
PPARβ-mutant skin reveals no defect in fetal and adult epider-
mal architecture, or in the expression of keratinocyte differenti-
ation markers (3). However, epidermal hyperplasia in response
to tetradecanoylphorbol acetate (TPA) treatment was enhanced
in PPARβ-mutant animals, emphasizing the role for PPARβ in
the control of keratinocyte proliferation and differentiation
(3,25). Similarly, the slightly increased keratinocyte prolifera-
tion index in PPARβ heterozygous animals is also in favor of
the existence of such a control (3). Consistent with these obser-
vations, PPARβ expression is rapidly upregulated following
challenges that stimulate keratinocyte proliferation, such as hair
plucking or cutaneous injury, and skin wound healing is altered
in PPARβ-mutant mice (3), largely due to a disrupted balance
between proliferation and apoptosis (19,26), as well as to de-
fects in kera-tinocyte adhesion and migration (3,27).
Important roles of PPARα and PPARβ in human kera-
tinocyte differentiation were also reported (see Table 1). As
already mentioned, PPARβ is the predominant isotype in
these keratinocytes (10,11,28,29). Its expression remains high
and unchanged during the differentiation of cultured kera-
tinocytes, or during the stratification and keratinization of the
epidermis in in vitro reconstructed skin (10,28), whereas it in-
creases upon squamous differentiation in human tracheo-
bronchial epithelial cells (29). PPARα and PPARγ are expressed
at lower levels, but their expression increases upon keratinocyte
differentiation in similar models (10,28). In human ker-
atinocytes, PPARβ- (L-165041 and GW1514) and PPARα
(clofibrate and Wy-14,643)-selective agonists induce the expres-
sion of a number of epidermal differentiation markers, including
involucrin (10,20,30), whereas PPARγ ligands (BRL-49653 and
prostaglandin J2) have no effect (10,31). The hypothesis that
PPAR may also affect the metabolism of lipids in keratinocytes
is supported by the observation that PPARα ligand Wy-14,643
increased both the synthesis of cer-amides and cholesterol de-
rivatives in a human skin equivalent model (30). Also, the
PPARβ selective agonist GW1514 increases TG accumulation
and induces the adipose differentiation-related protein
(ADRP) and fasting-induced adipose factor (FIAF) expres-
sion in human keratinocytes, two proteins that have potential
important roles in lipid metabolism (20).
IMPLICATION OF PPAR IN HYPERPROLIFERATIVE
SKIN DISEASES
Based on their diverse biological effects on keratinocyte pro-
liferation and differentiation, PPAR ligands may become in-
teresting compounds for the treatment of various epidermal
disorders characterized by inflammation, keratinocyte hyper-
proliferation, and aberrant differentiation, such as psoriasis.
In support of an involvement of PPAR in psoriatic epidermis,
PPARβ expression was reported to be dramatically increased
in the hyperproliferative lesional skin from psoriatic patients
(11,28), probably as a response to pro-inflammatory signals
in the lesions. It is indeed well established that PPARβ gene
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TABLE 1
Effects of Peroxisome Proliferator-Activated Receptor Agonists in Various Cell Types of the Skina
Cell types Rodents Human
Keratinocytes α differentiation in vitro (WY; CLO; OA) differentiation (WY; CLO; OA) (15;30;31)
(12;14;17) and in vivo (WY; CLO) (13;15) lipid accumulation (WY) (20;30)
proliferation in vivo (WY; CLO) (15;17) proliferation (WY; CLO) (10;31)
β differentiation in vitro (LD; LA) (12;19) differentiation (LD; GW; TTA) (10;20)
and in vivo (GW) (20) lipid accumulation (GW) (20)
No effect on proliferation in vivo (GW) (20) No effect on proliferation (LD) (10)
γ No significant effect on differentiation No effect on differentiation (BRL; PGJ2) (10;31)
in vitro (TRO; PGJ2) (12) proliferation (TRO; BRL) (10;33)
Hair follicles α nd survival of cultured hair follicles (CLO) (34)
and melanocytes proliferation and melanogenesis in melanocytes (WY) (42)
β nd No effect on proliferation and melanogenesis
in melanocytes (BEZ) (42)
γ nd proliferation and melanogenesis in melanocytes (CIG) (42)
Sebocytes α differentiation (WY) (36;37;39) No effect on differentiation (WY) (38)
No effect on proliferation (WY) (39)
β differentiation (LA; PGI2) (36;37;39) differentiation (LA) (38)
proliferation (PGI2) (39)
γ differentiation (TRO; BRL) (36;37;39) No effect on differentiation (CIG) (38)
No effect on proliferation (TRO) (39)
aThis table summarizes the stimulatory ( ) or inhibitory ( ) effects of treatment with PPARα (α), PPARβ (β), and PPARγ (γ) agonists on the differ-
entiation and proliferation in various cell types derived from rat and mouse (Rodents) as well as human (Human) skin. These results were obtained
in in vitro studies, except in rodent keratinocytes where both in vitro and in vivo experiments were performed. Effects of PPAR ligands on the dif-
ferentiation of hair follicles and melanocytes in rodents have not been determined (nd). PPAR agonists used in each study are indicated as follows:
BEZ, bezafibrate; BRL, BRL-49653; CIG, ciglitazone; CLO, clofibrate; GW, GW1514; LA, linoleic acid; LD, L-165041; OA, oleic acid; PGI2, car-
baprostacyclin; PGJ2, 15-deoxy-prostaglandin J2; TRO, troglitazone; TTA, tetradecylthoacetic acid; WY, Wy-14,643.
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expression is upregulated in mouse skin in response to
inflammatory cytokines, such as tumor necrosis factor alpha
(TNF-α) (19). In addition, putative PPARβ ligands, such as
lipoxygenase products, are generated at high levels in psori-
atic skin lesions, and may therefore activate the increased
amount of PPARβ (11). The fact that PPARβ is probably nat-
urally highly active in the psoriatic lesions may explain why
the PPARβ agonist tetradecylthioacetic acid has no strong anti-
psoriatic effect when applied topically (32). By contrast to
PPARβ expression, no or little change in the cutaneous levels
of PPARα and PPARγ was observed in lesional psoriatic skin
(11,28), and the PPARα (clofibrate) and PPARγ (rosiglita-
zone) agonists had no effect when applied on psoriasis plaques
(32). Nevertheless, it is encouraging to note that treatment
with the synthetic PPARγ agonist troglitazone was reported
to normalize the histological characteristics of psoriatic skin
in organ culture, and to reduce the epidermal hyperplasia of
psoriasis in the severe combined immunodeficient mouse and
human skin transplant model of psoriasis (33). Finally, two
PPARα ligands (Wy-14,643 and clofibrate) were able to re-
store epidermal homeostasis in subacute and chronic models
of hyperproliferative epidermis in hairless mice (17), even
though these models do not perfectly mimic psoriatic or other
human disorders. Obviously, further in vivo and clinical stud-
ies are needed to better define the potentially beneficial roles
of PPAR in this pathology.
ROLE OF PPARS IN HAIR FOLLICLE 
AND SEBOCYTE DIFFERENTIATION
Skin epithelial progenitor cells give rise to the epidermis, as
well as to the epithelial component of skin appendages, in-
cluding hair follicles and their associated sebaceous glands.
Hair follicle morphogenesis is governed by complex bidirec-
tional interactions between epithelial keratinocytes and the
underlying dermal cells of the mesenchymal condensations
(Fig. 2). These interactions control a tight balance between
keratinocyte proliferation and apoptosis. In rodents, all three
PPAR isotypes are expressed in the differentiating hair folli-
cles from the early embryonic developmental stages (Fig. 2).
PPAR remain highly expressed in postnatal and adult hair fol-
licles, whereas they disappear from the interfollicular epider-
Lipids, Vol. 39, no. 11 (2004)
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FIG. 2. Schematic representation of murine hair follicle morphogenesis. Hair follicle develop-
ment occurs between embryonic day 14.5 (E14.5) and postnatal day 7 (P7) in mouse, and is
governed by bidirectional epithelial–mesenchymal interactions between epithelial kera-
tinocytes and dermal fibroblasts of underlying mesenchymal condensations. Following dermal
induction, hair follicle precursors appear first as thickening of the uniform epithelial surface
(placode, E14.5). Follicular epithelial cells will next proliferate, followed by downgrowth into
the dermis, leading to the elongation of hair follicles (Newborn), and will finally differentiate
into the typical structures of mature hair follicles, including root sheaths, hair matrix, and hair
shaft (Adult) (46). In parallel, melanin starts to be produced in the precortex region, and the
first sebocytes form the sebaceous gland (Newborn). Expression patterns of PPARα (α), PPARβ
(β), and PPARγ (γ) determined or not (nd) in mouse (8), rat (10), and human (35) hair follicles
at indicated stages, as well as in mature sebaceous glands (8,28,39), are given in the bottom
panels.
mis after birth (3,8), as already mentioned (see Figs. 1, 2). A
detailed analysis of the expression of PPAR in human hair fol-
licles shows that they are specifically located in both epithe-
lial and dermal hair follicle cells (34). In addition, the PPARα
ligand clofibrate was reported to increase the survival of
human hair follicles in vitro, within a narrow range of con-
centrations (Table 1) (34). Although a possible function of the
two other PPAR isotypes in hair follicle growth has not yet
been examined, it is interesting to note that conditional abla-
tion in the murine epidermis of RXRα, the most abundant
heterodimeric partner of PPARs in keratinocytes, results in
delayed hair follicle maturation and alopecia (35).
Chronologically, the latest differentiated cell type to ap-
pear in the developing follicle is the oil-rich sebocytes. They
arise from cells within the superficial hair follicle and will
eventually form a gland located outside the hair follicle. Se-
baceous lipogenesis, leading to the accumulation of lipid
droplets and finally to sebum excretion, represents a major
step in the differentiation process and differentiated state of
sebaceous gland cells. Rodent and human sebocytes were
shown to express the three PPAR, either in cell culture or in
vivo (Fig. 2), the predominant isotype being PPARβ (9,24,36−
38). Consistently, and in addition to androgens that are well
known to regulate the growth and maturation of sebocytes,
PPAR agonists and retinoids were recently found to affect se-
baceous gland differentiation (see Table 1). Activation of
PPARγ and PPARα by respective selective agonists has no ef-
fect on sebocyte growth (39), but stimulates lipid droplet ac-
cumulation in cultured rat preputial sebocytes, as assessed
histochemically using Oil Red O staining (36,37). This effect
was not observed in epidermal cells (37) or in cultured human
sebocytes (38), possibly due to the different selective PPAR
agonists or to various ligand concentrations used in each
study. In parallel, RXR selective ligands have prominent dif-
ferentiative and weak proliferative effects on sebocytes (40).
The RXRα selective rexinoid CD2809 also amplified the pro-
differentiative effect of PPAR in preputial sebocytes, suggesting
a cooperation between PPAR and RXR agonists in promoting
differentiation of these cells (39). In both rat and human cul-
tured sebocytes, the pan PPAR(α/β) activators carbaprostacy-
clin and linoleic acid were more effective than PPARα or
PPARγ agonists in stimulating sebocyte lipid droplet forma-
tion, suggesting an important contribution of PPARβ in this
process (37–39). Interestingly, PPARβ seems more important
in the late stages of sebocyte differentiation (37,38), whereas
it was involved in the early adipocyte differentiation (41),
suggesting that it plays different roles in the differentiation
program of each cell type.
It is noteworthy that, in spite of the relative importance of
PPAR in lipid metabolism and their high expression in sebo-
cytes, in neither PPARα nor PPARβ mutant mouse models
has sebaceous gland function been closely examined so far.
In contrast, inactivation of the PPARγ gene has underscored a
crucial contribution of PPARγ in sebocyte differentiation, 
although it appears dispensable for epidermal differentiation.
Indeed, and as already discussed, chimeric mice for PPARγ-
null and wild-type cells showed little or no contribution of
mutant cells to the development of sebaceous glands, suggest-
ing that PPARγ-null cells cannot develop into sebocytes (24).
NEW PUTATIVE FUNCTION OF PPARS IN
MELANOCYTE DIFFERENTIATION
The pigment-producing cells of the skin are called melano-
cytes and their activity is the major determinant of the color
of the hair and skin. Melanocytes originate from the neural
crest and migrate to the basal layer of the epidermis and the
hair matrix during embryogenesis. Interestingly, all three
PPAR were detected in cultured human melanocytes (42) and
in melanoma cells (43). Consistent with the role of PPAR ag-
onists in cellular proliferation and differentiation in kera-
tinocytes, PPARα (Wy-14,643) and PPARγ (ciglitazone) ligands
were shown to inhibit the proliferation and to stimulate the
melanin synthesis of cultured melanocytes (Table 1), whereas
bezafibrate, a preferential activator for PPARβ in Xenopus
(44), had no effect on melanin content (42). In agreement with
this study, several PPARγ agonists, including troglitazone and
rosiglitazone, were previously demonstrated to inhibit cell
growth in human malignant melanoma (43), and topical appli-
cation of retinoic acid was shown to improve hyperpigmented
skin lesions such as melasma (45). Because of their antipro-
liferative and prodifferentiative effect on melanocytes, it is
tempting to suggest that PPAR and RXR ligands may be ben-
eficial in the treatment of melanomas. However, too little is
known in this context for the moment, and further investiga-
tion is needed.
DISCUSSION AND HYPOTHESIS
These studies suggest that PPARα may contribute to seba-
ceous gland differentiation and epidermal permeability bar-
rier formation by increasing both lipid metabolism and ex-
pression of structural differentiation markers, whereas PPARγ
plays a unique role in stimulating sebocyte function. Further-
more, PPARβ was identified as the predominant isotype in the
skin, and as a modulator of cell differentiation in both ker-
atinocytes and sebocytes.
Because of their diverse biological activities in epidermal
processes such as keratinocyte proliferation and differentia-
tion, PPAR may represent a major research target for the un-
derstanding and treatment of many skin diseases resulting in
disturbance of normal tissue homeostasis and epidermal hy-
perproliferation, such as benign epidermal tumors, papillo-
mas, melanomas, and psoriasis. In addition, due to the in-
creasing number of studies implicating PPAR in the control
of sebocyte differentiation, the development of PPAR antago-
nists that can interfere selectively with sebum production may
constitute an important element in the prevention of acne vul-
garis, characterized by excess sebum production.
Lipids, Vol. 39, no. 11 (2004)
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